Data Sheet (Cat.No.T28277)

TargetMol

OXA-11

Chemical Properties



CAS No. : 1257994-15-2

Formula: C37H49F3N7O5P

Molecular Weight: 759.8

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	OXA-11 (FAK-IN-16) is an orally active, selective focal adhesion kinase (FAK) inhibitor with antitumor activity. It inhibits FAK phosphorylation at tyrosine 397 in a dose-dependent manner and suppresses TOV21G tumor growth. It is used in cancer research.
Targets(IC50)	FAK
In vitro	OXA-11 is a selective photophosphorylation inhibitor of plaque adhesion kinase (FAK) with an IC50 of 1.2 pM. In 3-D culture, OXA-11 inhibited the proliferation of tumor cells, with EC50 of 9 nM in TOV21G cells and 0.3 nM in IGROV1 cells, and promoted apoptosis of tumor cells, with EC50 of 31 nM in TOV21G cells. The EC50 of IGROV1 cells was 0.5 nM. [1]
In vivo	Intragastric administration of OXA-11 (40-120 mg/kg, soluble in 20% Trappsol) can reduce tumor vascular distribution and infiltration in mice, and when administered together with anti-VEGFR-2 antibody DC101, can reduce pancreatic neuroendocrine tumor metastasis in RIP-Tag2 mice. [1]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3161 mL	6.5807 mL	13.1614 mL
5 mM	0.2632 mL	1.3161 mL	2.6323 mL
10 mM	0.1316 mL	0.6581 mL	1.3161 mL
50 mM	0.0263 mL	0.1316 mL	0.2632 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Moen I, et al. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis. 2015 Dec;32(8):799-817.

Appari RD, et al. US008399433B Amino pyrimidine anticancer compounds. 2013:1-310. Issued by: United States Patent and Trademark Office. Issue Date: March 19, 2013. Assignee: OSI Pharmaceuticals, LLC, Farmingdale.

Wang C, Cheng YQ. Thailandepsin a. Acta Crystallogr Sect E Struct Rep Online. 2011 Nov;67(Pt 11):o2948-9. doi: 10.1107/S1600536811041390. PubMed PMID: 22219976; PubMed Central PMCID: PMC3247358.

Yang D, Guo Y, Zhang Z. Combined porin loss and extended spectrum beta-lactamase production is associated with an increasing imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains. Curr Microbiol. 2009 Apr;58(4):366-70. doi: 10.1007/s00284-009-9364-4. PubMed PMID: 19219497.